Artelo Bioscienc Financials
This page shows Artelo Bioscienc (ATLEW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Artelo Bioscienc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Artelo Bioscienc generates $0.66 in operating cash flow (-$8.5M OCF vs -$12.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Artelo Bioscienc earns $-58.8 in operating income for every $1 of interest expense (-$11.4M vs $194K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Artelo Bioscienc reported -$12.9M in net income in fiscal year 2025. This represents a decrease of 31.1% from the prior year.
Artelo Bioscienc earned $-12.52 per diluted share (EPS) in fiscal year 2025. This represents an increase of 31.6% from the prior year.
Artelo Bioscienc held $600K in cash against $0 in long-term debt as of fiscal year 2025.
Artelo Bioscienc had 2M shares outstanding in fiscal year 2025. This represents an increase of 255.7% from the prior year.
Artelo Bioscienc invested $5.4M in research and development in fiscal year 2025. This represents a decrease of 9.5% from the prior year.
ATLEW Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $1.3M-31.9% | $1.9M+35.2% | $1.4M | N/A | $325K-80.7% | $1.7M+11.8% | $1.5M |
| SG&A Expenses | N/A | $1.8M+41.8% | $1.3M+28.5% | $995K | N/A | $870K+5.2% | $827K-23.6% | $1.1M |
| Operating Income | N/A | -$3.1M+1.9% | -$3.1M-32.4% | -$2.4M | N/A | -$1.2M+52.4% | -$2.5M+3.0% | -$2.6M |
| Interest Expense | N/A | $111K+54.2% | $72K | N/A | N/A | $0 | $0 | N/A |
| Income Tax | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | N/A | -$3.1M+3.1% | -$3.2M-35.8% | -$2.4M | N/A | -$1.1M+53.5% | -$2.4M+2.0% | -$2.5M |
| EPS (Diluted) | N/A | $-3.97+29.2% | $-5.61-29.3% | $-4.34 | N/A | $-2.10+53.5% | $-4.52+3.0% | $-4.66 |
ATLEW Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.8M-34.4% | $4.3M-2.1% | $4.4M+24.0% | $3.5M-25.2% | $4.7M-34.2% | $7.1M-14.3% | $8.3M-19.6% | $10.4M |
| Current Assets | $695K-62.0% | $1.8M-18.2% | $2.2M+61.6% | $1.4M-46.0% | $2.6M-48.7% | $5.0M-19.2% | $6.2M-24.7% | $8.2M |
| Cash & Equivalents | $600K-65.1% | $1.7M-16.7% | $2.1M+176.9% | $746K-68.1% | $2.3M-46.3% | $4.4M+394.6% | $881K-26.3% | $1.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.1M-16.9% | $4.9M-15.0% | $5.8M+101.3% | $2.9M+55.5% | $1.8M+137.5% | $775K-24.5% | $1.0M+25.7% | $817K |
| Current Liabilities | $4.0M-16.8% | $4.9M-14.9% | $5.7M+103.7% | $2.8M+58.2% | $1.8M+154.2% | $697K-25.9% | $940K+30.4% | $721K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$1.3M-100.9% | -$633K+55.0% | -$1.4M-315.6% | $652K-77.2% | $2.9M-55.1% | $6.4M-12.9% | $7.3M-23.5% | $9.5M |
| Retained Earnings | -$63.0M-7.1% | -$58.8M-5.6% | -$55.7M-6.1% | -$52.5M-4.7% | -$50.1M-8.1% | -$46.4M-2.5% | -$45.2M-5.7% | -$42.8M |
ATLEW Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M+16.8% | -$3.5M-580.5% | -$514K+67.8% | -$1.6M+37.8% | -$2.6M-229.9% | -$778K+62.3% | -$2.1M+29.9% | -$2.9M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $188K+175.2% | -$250K | $0 | $0-100.0% | $500K-88.2% | $4.3M+142.9% | $1.8M+37.9% | $1.3M |
| Financing Cash Flow | $1.6M-53.3% | $3.4M+89.6% | $1.8M | $0-100.0% | $57K | $0 | $0-100.0% | $55K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ATLEW Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | -73.1%+0.8pp | -73.9%-6.5pp | -67.5% | N/A | -15.9%+13.4pp | -29.2%-5.2pp | -24.0% |
| Current Ratio | 0.17-0.2 | 0.38-0.0 | 0.39-0.1 | 0.49-1.0 | 1.44-5.7 | 7.15+0.6 | 6.56-4.8 | 11.36 |
| Debt-to-Equity | -3.20+4.5 | -7.74-3.6 | -4.10-8.5 | 4.39+3.7 | 0.64+0.5 | 0.12-0.0 | 0.14+0.1 | 0.09 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.17), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
Is Artelo Bioscienc profitable?
No, Artelo Bioscienc (ATLEW) reported a net income of -$12.9M in fiscal year 2025.
What is Artelo Bioscienc's earnings per share (EPS)?
Artelo Bioscienc (ATLEW) reported diluted earnings per share of $-12.52 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Artelo Bioscienc's operating cash flow?
Artelo Bioscienc (ATLEW) generated -$8.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Artelo Bioscienc's total assets?
Artelo Bioscienc (ATLEW) had $2.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Artelo Bioscienc spend on research and development?
Artelo Bioscienc (ATLEW) invested $5.4M in research and development during fiscal year 2025.
How many shares does Artelo Bioscienc have outstanding?
Artelo Bioscienc (ATLEW) had 2M shares outstanding as of fiscal year 2025.
What is Artelo Bioscienc's current ratio?
Artelo Bioscienc (ATLEW) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Artelo Bioscienc's debt-to-equity ratio?
Artelo Bioscienc (ATLEW) had a debt-to-equity ratio of -3.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Artelo Bioscienc's return on assets (ROA)?
Artelo Bioscienc (ATLEW) had a return on assets of -459.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Artelo Bioscienc's cash runway?
Based on fiscal year 2025 data, Artelo Bioscienc (ATLEW) had $600K in cash against an annual operating cash burn of $8.5M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Artelo Bioscienc's debt-to-equity ratio negative or unusual?
Artelo Bioscienc (ATLEW) has negative shareholder equity of -$1.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Artelo Bioscienc's Piotroski F-Score?
Artelo Bioscienc (ATLEW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Artelo Bioscienc's earnings high quality?
Artelo Bioscienc (ATLEW) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Artelo Bioscienc cover its interest payments?
Artelo Bioscienc (ATLEW) has an interest coverage ratio of -58.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.